Cim Investment Management Inc Halozyme Therapeutics, Inc. Transaction History

Cim Investment Management Inc

$522 Million
Q2 2025

A detailed history of Cim Investment Management Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Cim Investment Management Inc holds 17,924 shares of HALO stock, worth $1.17 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

17,924

Previous 8,929 100.74%

Holding current value

$1.17 Million

Previous $569,000 63.8%

% of portfolio

0.18%

Previous 0.13%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 22, 2025	BUY	$47.91 - $70.14 $430,950 - $630,909	8,995 Added 100.74%	17,924 $932,000
Q1 2025 Jun 02, 2025	SELL	$47.74 - $65.16 $10,168 - $13,879	-213 Reduced 2.33%	8,929 $569,000
Q2 2024 Aug 15, 2024	SELL	$37.81 - $52.4 $82,425 - $114,232	-2,180 Reduced 19.25%	9,142 $478,000
Q1 2024 May 07, 2024	BUY	$33.68 - $41.95 $112,188 - $139,735	3,331 Added 41.68%	11,322 $460,000
Q2 2023 Aug 09, 2023	BUY	$30.28 - $38.74 $82,846 - $105,992	2,736 Added 52.06%	7,991 $288,000
Q1 2023 May 16, 2023	BUY	$32.86 - $55.7 $172,679 - $292,703	5,255 New	5,255 $200,000
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $60,492 - $81,294	1,570 Added 25.33%	7,769 $307,000
Q2 2022 Sep 02, 2022	BUY	$37.35 - $48.3 $40,748 - $52,695	1,091 Added 21.36%	6,199 $273,000
Q1 2022 May 17, 2022	SELL	$31.97 - $41.06 $19,309 - $24,800	-604 Reduced 10.57%	5,108 $204,000
Q4 2021 May 19, 2022	SELL	$31.82 - $40.75 $181,755 - $232,764	-5,712 Reduced 50.0%	5,712 $230,000
Q4 2021 Feb 02, 2022	BUY	$31.82 - $40.75 $181,755 - $232,764	5,712 Added 100.0%	11,424 $462,000
Q1 2021 May 20, 2021	BUY	$39.51 - $51.45 $225,681 - $293,882	5,712 New	5,712 $238,000

Others Institutions Holding HALO

# of Institutions

631

Shares Held

127M

Call Options Held

408K

Put Options Held

384K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $9.08B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cim Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cim Investment Management Inc with notifications on news.

Account

Cim Investment Management Inc Halozyme Therapeutics, Inc. Transaction History